Publications by authors named "Jason Exter"

Claim this Profile
G
GOULD EDU: Cluster-Randomized Trial of an Educational Intervention to Improve Lipid-Lowering Guideline Adherence.
Christopher P Cannon, Christie M Ballantyne, Deepak L Bhatt, James A de Lemos, Qi Gao, Jason Exter

JACC Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician Perceptions, Knowledge, and Implementation of Lipid-Lowering Guidelines in the USA.
Taruja Karmarkar, Lori D Bash, Jason Exter, Jordana K Schmier, Sayeli P Jayade

J Gen Intern Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Public Health Gains from Improved Treatment of Hypercholesterolemia: A Simulation Study of NHANES Adults Treated to Guideline-Directed Therapy.
G Caleb Alexander, Jill Curran, Alejandro Victores, Hemalkumar B Mehta, Shanshan Lin, Jason Exter

J Gen Intern Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B.
Ronald M Witteles, Pablo Garcia-Pavia, Thibaud Damy, Martha Grogan, Farooq H Sheikh, Jason Exter

J Am Coll Cardiol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction.
Swati Sakhuja, Vera A Bittner, Todd M Brown, Michael E Farkouh, Emily B Levitan, Jason Exter

Cardiovasc Drugs Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical solutions for implementation of blood cholesterol guidelines in clinical practice.
Gregory Piazza, Nihar R Desai, Usman Baber, Jason Exter, Bethany Kalich

Trends Cardiovasc Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD.
Emily C McKinley, Vera A Bittner, Todd M Brown, Ligong Chen, Jason Exter

Cardiovasc Drugs Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019.
Alexander R Zheutlin, Catherine G Derington, Jennifer S Herrick, Robert S Rosenson, Bharat Poudel, Jason Exter

Circ Cardiovasc Qual Outcomes· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline.
Chibuike J Alanaeme, Vera Bittner, Todd M Brown, Lisandro D Colantonio, Nafeesa Dhalwani, Jason Exter

Am Heart J Plus· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating a Simple Approach to Identify Adults Meeting the 2018 AHA/ACC Cholesterol Guideline Definition of Very High Risk for Atherosclerotic Cardiovascular Disease.
Paul Muntner, Kate K Orroth, Katherine E Mues, Jason Exter, Erin D Shannon

Cardiovasc Drugs Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008-2019.
Sara N Levintow, Stephanie R Reading, Sina Noshad, Sophie E Mayer, Catherine Wiener, Jason Exter

Clin Epidemiol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab.
Nihar R Desai, Rolin L Wade, Pin Xiang, Lionel Pinto, Sasikiran Nunna, Jason Exter

Clin Cardiol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ischemic Event Rates in Very-High-Risk Adults.
Lisandro D Colantonio, Erin D Shannon, Kate K Orroth, Rebecca Zaha, Elizabeth A Jackson, Jason Exter

J Am Coll Cardiol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis